BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schieren G, Wirtz N, Altmeyer P, Rump LC, Weiner SM, Kreuter A. Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options. J Am Acad Dermatol. 2009;61:868-874. [PMID: 19836645 DOI: 10.1016/j.jaad.2009.03.040] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Shreberk-Hassidim R, Zaguri R, Maly A, Zlotogorski A, Ramot Y. Skin manifestations of primary hyperoxaluria: a case report. Int J Dermatol 2015;54:e478-9. [PMID: 26227278 DOI: 10.1111/ijd.13036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Wiesinger B, Kehlbach R, Hemsen J, Bebin J, Bantleon R, Schwenzer N, Spira D, Claussen CD, Wiskirchen J. Effects of magnetic resonance imaging contrast agents on human umbilical vein endothelial cells and evaluation of magnetic resonance imaging contrast media-triggered transforming growth factor-beta induction in dermal fibroblasts (HSF) as a model for nephrogenic systemic fibrosis. Invest Radiol 2011;46:71-6. [PMID: 21139503 DOI: 10.1097/RLI.0b013e31820218e9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Ross C, De Rosa N, Marshman G, Astill D. Nephrogenic systemic fibrosis in a gadolinium-naïve patient: Successful treatment with oral sirolimus: Sirolimus and NSF. Australasian Journal of Dermatology 2015;56:e59-62. [DOI: 10.1111/ajd.12176] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
4 Wu M, Hou P, Dong L, Cai L, Chen Z, Zhao M, Li J. Manganese dioxide nanosheets: from preparation to biomedical applications. Int J Nanomedicine 2019;14:4781-800. [PMID: 31308658 DOI: 10.2147/IJN.S207666] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
5 Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31:149-162. [PMID: 27322218 DOI: 10.1002/jca.21470] [Cited by in Crossref: 168] [Cited by in F6Publishing: 176] [Article Influence: 42.0] [Reference Citation Analysis]
6 Lohani S, Golenbiewski J, Swami A, Halalau A. A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR. BMJ Case Rep 2017;2017:bcr-2017-221016. [PMID: 29025775 DOI: 10.1136/bcr-2017-221016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
7 Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
8 Galperin TA, Cronin AJ, Leslie KS. Cutaneous manifestations of ESRD. Clin J Am Soc Nephrol. 2014;9:201-218. [PMID: 24115194 DOI: 10.2215/cjn.05900513] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
9 Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases. JACC Cardiovasc Imaging 2011;4:1206-16. [PMID: 22093272 DOI: 10.1016/j.jcmg.2011.08.013] [Cited by in Crossref: 70] [Cited by in F6Publishing: 49] [Article Influence: 7.8] [Reference Citation Analysis]
10 Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol 2021;10:29-36. [PMID: 34136369 DOI: 10.5527/wjn.v10.i3.29] [Reference Citation Analysis]
11 Schieren G, Gambichler T, Skrygan M, Burkert B, Altmeyer P, Rump LC, Kreuter A. Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. Am J Kidney Dis 2010;55:1040-9. [PMID: 20430497 DOI: 10.1053/j.ajkd.2010.01.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nashel J, Steen V. Scleroderma mimics. Curr Rheumatol Rep 2012;14:39-46. [PMID: 22131103 DOI: 10.1007/s11926-011-0220-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
13 Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171-354. [PMID: 31180581 DOI: 10.1002/jca.21705] [Cited by in Crossref: 314] [Cited by in F6Publishing: 247] [Article Influence: 157.0] [Reference Citation Analysis]
14 Waikhom R, Taraphder A. Nephrogenic systemic fibrosis: a brief review. Indian J Dermatol. 2011;56:54-58. [PMID: 21572794 DOI: 10.4103/0019-5154.77554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]